CapWealth Advisors LLC Sells 7,924 Shares of CVS Health Corporation $CVS

CapWealth Advisors LLC trimmed its position in shares of CVS Health Corporation (NYSE:CVS) by 2.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 318,909 shares of the pharmacy operator’s stock after selling 7,924 shares during the quarter. CVS Health accounts for approximately 1.6% of CapWealth Advisors LLC’s portfolio, making the stock its 24th largest holding. CapWealth Advisors LLC’s holdings in CVS Health were worth $24,043,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Diversified Trust Co grew its position in shares of CVS Health by 69.3% during the 2nd quarter. Diversified Trust Co now owns 7,370 shares of the pharmacy operator’s stock valued at $508,000 after acquiring an additional 3,018 shares during the period. Park Avenue Securities LLC lifted its stake in CVS Health by 72.4% in the second quarter. Park Avenue Securities LLC now owns 44,641 shares of the pharmacy operator’s stock valued at $3,079,000 after purchasing an additional 18,751 shares during the last quarter. U.S. Capital Wealth Advisors LLC grew its holdings in CVS Health by 3.1% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 13,155 shares of the pharmacy operator’s stock valued at $907,000 after purchasing an additional 400 shares during the period. Waycross Partners LLC purchased a new stake in CVS Health in the second quarter worth $3,104,000. Finally, Norden Group LLC lifted its position in shares of CVS Health by 3.0% during the 2nd quarter. Norden Group LLC now owns 35,114 shares of the pharmacy operator’s stock valued at $2,422,000 after buying an additional 1,010 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Price Performance

Shares of NYSE CVS opened at $81.49 on Thursday. The stock’s 50-day simple moving average is $78.88 and its two-hundred day simple moving average is $74.56. CVS Health Corporation has a twelve month low of $52.34 and a twelve month high of $85.15. The firm has a market capitalization of $103.44 billion, a P/E ratio of 214.44, a P/E/G ratio of 0.74 and a beta of 0.48. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping the consensus estimate of $1.36 by $0.24. The company had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.CVS Health’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Thursday, January 22nd. CVS Health’s payout ratio is currently 700.00%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CVS shares. Royal Bank Of Canada reissued an “outperform” rating on shares of CVS Health in a report on Thursday, December 4th. JPMorgan Chase & Co. lifted their target price on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Morgan Stanley boosted their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Finally, Mizuho boosted their target price on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Nineteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and a consensus target price of $94.86.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.